基于WGCNA分析和SVM建模对轻度认知功能障碍患者血液基因生物标志物的筛选研究

程丽珍; 郭起浩; 李蔚; 陈奕馨; 苗雅

doi:10.13406/j.cnki.cyxb.002922

您当前的位置：

首页 >

文章列表页 >

基于WGCNA分析和SVM建模对轻度认知功能障碍患者血液基因生物标志物的筛选研究

认知障碍与外周生物标志物关系研究 | 更新时间：2022-06-24

- 基于WGCNA分析和SVM建模对轻度认知功能障碍患者血液基因生物标志物的筛选研究
- Screening blood genetic biomarkers of patients with mild cognitive impairment based on weighted gene co-expression network analysis and support vector machine modeling
- 重庆医科大学学报 2021年46卷第11期页码：1334-1341
- 作者机构：
  
  上海交通大学附属第六人民医院老年病科，上海　200235
- 作者简介：
  
  [ "程丽珍，Email：lizcheng1112@163.com，研究方向：认知功能障碍。" ]
  苗雅，副主任医师，医学博士，硕导。上海医学会老年医学专科分会青年委员会副主任委员、中华医学会老年医学分会第十届委员会青年委员、上海市医学会老年医学专科分会第十届委员会神经精神学组委员、《实用老年医学》青年编委会编委、中国老年医学学会认知障碍分会第一届委员会神经心理量表评估学术工作委员会委员、中国女医师协会第一届老年医学专业委员会委员；承担国家自然科学基金、上海市科委自然科学基金及校局级课题多项；在国内外相关期刊发表论文20余篇，其中SCI收录10余篇。Email：nning-my@163.com。
- 基金信息：
  
  上海市自然科学基金资助项目(19ZR1438800)
- DOI：10.13406/j.cnki.cyxb.002922
  中图分类号： R749.16
- 纸质出版日期：2021-11-28，
  
  收稿日期：2021-07-05，
扫描看全文
程丽珍, 郭起浩, 李蔚, 等. 基于WGCNA分析和SVM建模对轻度认知功能障碍患者血液基因生物标志物的筛选研究[J]. 重庆医科大学学报, 2021,46(11):1334-1341.

Lizhen Cheng, Qihao Guo, Wei Li, et al. Screening blood genetic biomarkers of patients with mild cognitive impairment based on weighted gene co-expression network analysis and support vector machine modeling[J]. Journal of Shanxi Agricultural Sciences, 2021,46(11):1334-1341.
程丽珍, 郭起浩, 李蔚, 等. 基于WGCNA分析和SVM建模对轻度认知功能障碍患者血液基因生物标志物的筛选研究[J]. 重庆医科大学学报, 2021,46(11):1334-1341. DOI： 10.13406/j.cnki.cyxb.002922.

Lizhen Cheng, Qihao Guo, Wei Li, et al. Screening blood genetic biomarkers of patients with mild cognitive impairment based on weighted gene co-expression network analysis and support vector machine modeling[J]. Journal of Shanxi Agricultural Sciences, 2021,46(11):1334-1341. DOI： 10.13406/j.cnki.cyxb.002922.

摘要

目的：

分析轻度认知功能损害（mild cognitive impairment，MCI）患者的外周血表达谱数据，寻找MCI的基因生物标志物。

方法：

从GEO数据库下载GSE63063表达谱数据，采用加权基因共表达网络分析（weighted gene co-expression network analysis，WGCNA）明确与MCI相关的共表达模块，对最显著的模块进行功能富集分析，利用STRING数据库构建模块的蛋白互作（protein-protein interaction，PPI）网络，识别网络中的Hub基因，基于支持向量机（support vector machine，SVM）建立MCI的诊断模型，并进行受试者工作特征曲线（receiver operating characteristic curve，ROC）分析，检测其诊断能力。

结果：

通过WGCNA分析，发现9个与MCI相关的共表达模块，brown模块与MCI的相关性最强。通过MCC算法筛选出每个模块的前15个Hub基因，其中brown模块的Hub基因诊断能力最高，在训练集及验证集中的ROC曲线下面积分别为0.864、0.789。

结论：

brown模块的Hub基因可成为诊断MCI的潜在生物学标志物。

Abstract

Objective

To analyze the expression profile of peripheral blood of patients with mild cognitive impairment (MCI) and search for genetic biomarkers of MCI.

Methods

The expression profile data of GSE63063 was downloaded from GEO database. Weighted gene co-expression network analysis (WGCNA) was used to identify the co-expression modules related to MCI. Functional enrichment analysis was performed on the most significant module. Then

the protein-protein interaction (PPI) network of the module was constructed by STRING database

and the Hub genes in the network were identified to establish the diagnosis model of MCI which was established based on the support vector machine (SVM). Finally

the receiver operating characteristic (ROC) analysis was carried out to detect its diagnostic ability.

Results

Through WGCNA analysis

9 co-expression modules related to MCI were found and brown module had the strongest correlation with MCI. The top 15 Hub genes of each module were screened out by MCC algorithm

among which Hub gene of brown module had the highest diagnosis ability

and the area under the ROC curve in the training set and the verification set was 0.864 and 0.789 respectively.

Conclusion

Hub gene of brown module can be potential biomarkers for diagnosis of MCI.

关键词

阿尔茨海默病轻度认知功能障碍加权基因共表达网络分析生物标志物Hub基因

Keywords

Alzheimer's diseasemild cognitive impairmentweighted gene co-expression network analysisbiomarkersHub gene

references

Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallelarm, phase 3 trial[J]. Lancet, 2016, 388(10062):2873-2884.

Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease[J]. N Engl J Med, 2014, 370(4):322-333.

Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease[J]. N Engl J Med, 2014, 370(4):311-321.

Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer's disease[J]. N Engl J Med, 2019, 380(15):1408-1420.

JrJack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease[J]. Ann Neurol, 2012, 71(6):765-775.

Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement, 2011, 7(3):280-292.

Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis[J]. BMC Bioinformatics, 2008, 9:559.

Cao WN, Jiang YK, Ji X, et al. Identification of novel prognostic genes of triple-negative breast cancer using Meta-analysis and weighted gene co-expressed network analysis[J]. Ann Transl Med, 2021, 9(3):205.

Liao XW, Huang KT, Huang R, et al. Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy[J]. Onco Targets Ther, 2017, 10:4493-4506.

Chen R, Ge TT, Jiang WY, et al. Identification of biomarkers correlated with hypertrophic cardiomyopathy with co-expression analysis[J]. J Cell Physiol, 2019, 234(12):21999-22008.

Zhang ZY, Wang JJ, Chen O. Identification of biomarkers and pathogenesis in severe asthma by coexpression network analysis[J]. BMC Med Genomics, 2021, 14(1):51.

JrJack CR, Jr B, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease HHS public access author manuscript[J]. Alzheimers Dement, 2018, 14(4):535-562.

Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and Meta-analysis[J]. Lancet Neurol, 2016, 15(7):673-684.

Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia[J]. JAMA, 2019, 321(13):1286-1294.

Zou DH, Li RJ, Huang XH, et al. Identification of molecular correlations of RBM8A with autophagy in Alzheimer's disease[J]. Aging(Albany NY), 2019, 11(23):11673-11685.

Sood S, Gallagher IJ, Lunnon K, et al. A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status[J]. Genome Biol, 2015, 16:185.

Lunnon K, Ibrahim Z, Proitsi P, et al. Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood[J]. J Alzheimers Dis, 2012, 30(3):685-710.

Lian H, Yang L, Cole A, et al. NF-κB activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease[J]. Neuron, 2015, 85(1):101-115.

Thawkar BS, Kaur G. Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer's disease[J]. J Neuroimmunol, 2019, 326:62-74.

Jha NK, Jha SK, Kar R, et al. Nuclear factor-kappa β as a therapeutic target for Alzheimer's disease[J]. J Neurochem, 2019, 150(2):113-137.

Xing WQ, Sun HB, Yan C, et al. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules[J]. BMC Cancer, 2021, 21(1):263.

Liu XC, Yang Q, Zhang CY, et al. Multiregional-based magnetic resonance imaging radiomics combined with clinical data improves efficacy in predicting lymph node metastasis of rectal cancer[J]. Front Oncol, 2020, 10:585767.

Jiao ZQ, Ji YX, Zhang JH, et al. Constructing dynamic functional networks via weighted regularization and tensor low-rank approximation for early mild cognitive impairment classification[J]. Front Cell Dev Biol, 2020, 8:610569.

Tang RH, Liu HY. Identification of temporal characteristic networks of peripheral blood changes in Alzheimer's disease based on weighted gene co-expression network analysis[J]. Front Aging Neurosci, 2019, 11:83.

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

¹¹C-PIB-PET/CT与神经心理量表在轻度认知功能障碍和阿尔茨海默病中的相关性研究

神经丝轻链蛋白在阿尔茨海默病早期诊断中的作用研究

肠道菌群及其代谢产物作为阿尔茨海默病诊断生物标志物的研究进展

胰腺导管腺癌免疫检查点阻断耐药的生物标志物和治疗选择

生物信息学联合机器学习探究主动脉瓣膜钙化潜在的诊断标志物